



Universiteit
Leiden
The Netherlands

Strategies for optimal suppression of rheumatoid arthritis

Kooij, S.M. van der

Citation

Kooij, S. M. van der. (2009, January 22). *Strategies for optimal suppression of rheumatoid arthritis*. Retrieved from <https://hdl.handle.net/1887/13425>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13425>

Note: To cite this publication please use the final published version (if applicable).

STRATEGIES FOR OPTIMAL SUPPRESSION OF
RHEUMATOID ARTHRITIS

Proefschrift

TER VERKRIJGING VAN DE GRAAD VAN
DOCTOR AAN DE UNIVERSITEIT LEIDEN,
OP GEZAG VAN RECTOR MAGNIFICUS
PROF. MR. P.F. VAN DER HEIJDEN,
VOLGENS BESLUIT VAN
HET COLLEGE VOOR PROMOTIES
TE VERDEDIGEN OP
DONDERDAG 22 JANUARI 2009
KLOKKE 16.15 UUR
DOOR

Sjoerd Martijn van der Kooij
geboren te Leiderdorp
in 1976

PROMOTIECOMMISSIE

PROMOTORES	Prof. Dr. T.W.J. Huizinga Prof. Dr. B.A.C. Dijkmans <i>VU Medisch Centrum, Amsterdam</i>
COPROMOTORES	Dr. C.F. Allaart Dr. P.J.S.M. Kerstens <i>Jan van Breemen Instituut, Amsterdam</i>
REFERENT	Dr. R.F. van Vollenhoven <i>Karolinska Institutet, Stockholm</i>
OVERIGE LEDEN	Prof. Dr. F.C. Breedveld Prof. Dr. D.M.F.M. van der Heijde

The research presented in this thesis was performed at the Rheumatology Department of Leiden University Medical Centre, Leiden, The Netherlands. The research was financially supported by the Dutch College of Health Insurances, with additional funding by Schering-Plough B.V. and Centocor Inc.

© Sjoerd van der Kooij, 2008.

No Part of this thesis may be reproduced in any form without written permission from the author or, when appropriate, of the publishers of the publications.

ISBN 978-90-9023844-9

Foto omslag	Frans Jansen, Hollandse Hoogte
Vormgeving	Sam Gobin, Leiden
Druk	Drukkerij Mostert & Van Onderen, Leiden

Financial support for the publication of this thesis was provided by ABBOTT B.V., Amgen B.V., Artrose & Reuma Stichting, AstraZeneca B.V., Bristol-Myers Squibb B.V., Centocor B.V., J.E. Jurriaanse Stichting, MSD B.V., Pfizer B. V., het Reumafonds, Roche Nederland B.V., Schering-Plough B.V. en Teva Pharma NL.

INHOUD

- 1 General introduction – 7
 - 2 Innovative treatment strategies for patients with rheumatoid arthritis – 21
 - 3 Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score – 33
 - 4 Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score – 41
 - 5 A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis – 55
 - 6 Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent onset rheumatoid arthritis – 71
 - 7 Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis – 85
 - 8 Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis – 99
 - 9 General discussion and conclusion – 111
- Nederlandse Samenvatting – 119
- Role of the funding source – 125
- Acknowledgements – 125
- List of publications – 126
- Curriculum vitae – 127
- Dankwoord – 128